BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Inc. President and CEO Roderick De Greef had 11,101 shares of Common Stock withheld to cover taxes on restricted stock units that vested. These shares were delivered back to the company as a tax-withholding disposition, not sold on the open market. Following this transaction, he directly holds 733,746 shares of BioLife Solutions common stock.
BioLife Solutions Inc. reported an insider tax-withholding transaction by Chief Marketing Officer Todd Berard. On the release of restricted stock units, 1,879 shares of common stock were withheld by the company to cover his tax obligations. After this non-market disposition, Berard directly holds 164,061 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 1,681 shares of common stock at $19.12 per share to cover his tax obligations. After this withholding, Werner directly holds 48,251 shares of BIOLIFE SOLUTIONS common stock. This was not an open-market trade but an automatic share withholding mechanism tied to equity compensation.
BioLife Solutions Inc.'s Chief Financial Officer Troy Wichterman reported a routine tax-related share withholding tied to restricted stock vesting. On this Form 4, 3,749 shares of Common Stock were withheld at $19.12 per share to satisfy tax obligations that arose when restricted stock units were released.
These shares were not sold in the open market; they were retained by the company to cover taxes. After this transaction, Wichterman holds 216,900 shares of BioLife Solutions common stock directly, indicating he retains a substantial equity position following the RSU vesting event.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 931 shares of common stock to cover her tax obligations at $19.12 per share. After this withholding, she directly owns 92,429 shares. This was not an open-market sale but a standard mechanism tied to equity compensation vesting.
BioLife Solutions executive Karen A. Foster had shares withheld to cover taxes on equity compensation. On the release of restricted stock units, the company withheld 1,907 shares of Common Stock at a value of $19.12 per share to satisfy her tax obligations. After this tax-withholding disposition, she holds 111,335 shares of BioLife Solutions Common Stock directly.
BioLife Solutions EVP & Chief Scientific Officer Mathew Aby J. reported a routine tax-related share disposition. On the release of restricted stock units, 2,255 shares of common stock were withheld by the company at $19.12 per share to cover his tax obligations. After this withholding, he continues to directly own 390,682 shares of BioLife Solutions common stock, indicating that only a small portion of his overall holdings was affected and that this was not an open-market sale.
BioLife Solutions, Inc. (BLFS) officer Karen Foster reported a planned sale of 2,577 common shares, with an aggregate market value of $48,576.45 and an approximate sale date of March 23, 2026. She acquired 2,577 shares from the issuer through exercise of stock options on March 23, 2026, paying cash. The reported date for plan adoption or instruction, if relying on Rule 10b5-1, is December 4, 2025. Prior sales are identified as Rule 10b5-1 transactions.
BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades. After these sales, she directly owns 113,242 shares.
BioLife Solutions, Inc. (BLFS) filed a Form 144 reporting a transaction involving 500 common shares on 03/09/2026 tied to the exercise of stock options and settled for cash. The filing also lists recent 10b5-1 sales: 96,923 shares on 03/05/2026 for $1,953,163.22, 418 shares on 03/03/2026 for $8,669.32, and 335 shares on 01/06/2026 for $8,572.65.